<DOC>
	<DOCNO>NCT00297713</DOCNO>
	<brief_summary>ALTU-238 long act crystalline formulation recombinant human growth hormone ( rhGH ) develop treatment growth hormone deficiency adult child . ALTU-238 design require few injection currently available formulation rhGH .</brief_summary>
	<brief_title>Study Extended-Release , Crystalline Formulation Recombinant Human Growth Hormone ( ALTU-238 ) Growth Hormone Deficient Adults Determine Pharmacokinetics , Pharmacodynamics , Drug Safety</brief_title>
	<detailed_description />
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Growth hormone deficient men woman age 1860 year hypothalamic and/or pituitary structural lesion longstanding idiopathic GHD Growth hormone deficiency determine pituitary testing within last five year either two follow test : 1 . Insulin hypoglycemia ( glucose &lt; 50 mg/dL ) maximum GH &lt; 5 ng/mL ( 5 µg/L ) radioimmunoassay &lt; 2.5 µg/L , measure immunoradiometric assay 2 . ArginineGHRH infusion maximum GH &lt; 5 ng/mL ( 5 µg/L ) &lt; 2.5 µg/L , measure immunoradiometric assay Women must nonchild bear potential ( hysterectomy , tubal ligation , IUD acceptable ) three month prior enter study , postmenopausal ( menses one year ) , six twelve month without menses βestradiol level &lt; 20 pg/mL Glucocorticoid use allow provide subject physiologic ( &lt; 7.5 mg prednisone equivalent/day ) replacement dose least 3 month Free thyroxine ( T4 ) within normal range Screening . If subject receive thyroid hormone replacement therapy , dose must stable least 6 week prior Screening Willing able provide write informed consent BMI 20 36 kg/m2 Any previous ongoing clinically significant illness , opinion investigator , could prevent subject complete study Any history cancer within past 5 year , except dermal squamous basal cell carcinoma document 6month remission . Subjects recent history successfully treat cervical carcinoma situ exclude provide documented 12month remission BMI &lt; 20 &gt; 36 kg/m2 Any allergic abnormal reaction human growth hormone Inability subject discontinue use regularly prescribe human growth hormone treatment six week prior Day 1 completion study Serum creatinine &gt; 1.4 mg/dL Hypocalcemia hypercalcemia cause Hyperparathyroidism , osteomalacia disorder may affect bone bone marker include use bisphosphonates medication osteoporosis Participation another clinical trial 30 day prior screen Demonstrated inability comply protocol requirement ( e.g . uncooperative attitude , inability return followup visit , history medical noncompliance , and/or poor likelihood complete study ) Blood donation within 56 day screen visit Plasma donation within seven day screen visit Positive serum pregnancy test Women child bear potential Abuse alcohol ; determine principal investigator Abuse prescription illicit drug ; determine principal investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2006</verification_date>
</DOC>